Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD123-Targeted CAR-T in Myeloid Malignancies
NCT02937103Phase 2Unknown
- Sponsor
- Southwest Health System
- Start
- Oct 2016
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Anti-CD123-CAR-transduced T cells in myeloid leukemia (ML), sponsored by Southwest Health System. Primary endpoint: Adverse Events That Are Related to Treatment at 3 years. Status: unknown.
02
Drugs
Anti-CD123-CAR-transduced T cells
03
Conditions
myeloid leukemia (ML)
Beyond the preview
Go deeper on NCT02937103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937103.